Sotera Health Company (SHC) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals solid financial performance with raised EBITDA and EPS guidance, improved interest expenses, and strategic investments like the new X-ray facility. The Q&A indicates confidence in Sterigenics' and Nelson Labs' growth, despite some commercial segment challenges. The market cap suggests moderate sensitivity to positive news, likely resulting in a 2% to 8% stock price increase.
Key Financial Performance
Total Company Revenue (2025) $1.164 billion, a 5.7% increase year-over-year (5.2% on a constant currency basis). This growth was attributed to strong execution, growing demand for services, and disciplined financial management.
Adjusted EBITDA (2025) $593.8 million, an 8.2% increase year-over-year (7.8% on a constant currency basis). Margins expanded to 51%, an improvement of 118 basis points, driven by operational growth and cost management.
Adjusted Free Cash Flow (2025) $210 million. This reflects strong cash generation, positioning the company well for its long-term goals.
Sterigenics Revenue (2025) $198 million in Q4, a 10.6% increase year-over-year (8% on a constant currency basis). Growth was driven by favorable pricing (4.3%), volume and mix (3.7%), and foreign currency benefits (2.6%).
Nordion Revenue (2025) $50 million in Q4, a 12.3% decrease year-over-year. The decline was due to unfavorable volume and mix (-15%) from Cobalt-60 harvest timing, partially offset by favorable pricing (2.4%).
Nelson Labs Revenue (2025) $55 million in Q4, a 2.3% increase year-over-year (flat on a constant currency basis). Growth was driven by favorable pricing (3.2%) and foreign exchange (2.5%), offset by lower Expert Advisory Services revenue.
Interest Expense (2025) $156 million, a $9 million improvement year-over-year. This was driven by lower interest rates, favorable repricing of the term loan, and $86 million of debt paydown.
Net Income (2025) $78 million, or $0.27 per diluted share. Adjusted EPS was $0.86, an increase of $0.16 year-over-year, driven by operational growth, a lower tax rate, and improved interest expense.
Capital Expenditures (2025) $138 million. This reflects investments in growth and operational improvements.
Liquidity (2025) $940 million as of December 31, 2025, including $345 million of unrestricted cash and nearly $600 million of capacity under the revolving credit facility.
Net Leverage (2025) 3.2x, improved from 3.7x in 2024, reflecting debt reduction and EBITDA growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
X-ray facility construction: Significant progress made on the EO facility enhancements program and the construction of the new X-ray facility, planned to open in 2026.
Revenue growth: Total company revenue increased 5.7% to $1.164 billion in 2025, with Sterigenics and Nordion achieving 8% and 9% constant currency revenue growth, respectively.
Customer satisfaction: Customer satisfaction exceeded 80%, reflecting strong service delivery.
Adjusted EBITDA: Adjusted EBITDA increased 8.2% to $593.8 million in 2025, with margins expanding to 51%.
Debt reduction: Paid down $86 million of debt, reducing borrowing costs by 75 basis points and saving $13 million in annual interest.
Free cash flow: Delivered adjusted free cash flow of $210 million in 2025.
Corporate governance: Strengthened governance with the appointment of a lead independent director and welcomed Richard Kyle to the Board.
Long-term planning: 2025 marked the first year of the 2025-2027 long-range plan, with progress made towards achieving outlined goals.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Cobalt-60 harvest timing: Nordion's revenue decreased due to the timing of Cobalt-60 harvest schedules, leading to unfavorable volume and mix, which negatively impacted segment income and margins.
Inflation impact: Sterigenics faced challenges from inflation, which partially offset favorable pricing and volume mix.
Lower Expert Advisory Services revenue: Nelson Labs experienced a decline in revenue from Expert Advisory Services, which negatively impacted overall segment income.
Higher costs at Nelson Labs: Nelson Labs faced higher costs, which partially offset growth in core lab testing and favorable pricing.
Interest expense: Although interest expense improved, it remains a significant cost at $135 million to $145 million projected for 2026, impacting financial performance.
Depreciation increase: Depreciation costs are expected to increase in 2026, consistent with the step-up experienced in 2025, which could pressure financial results.
Capital expenditures: Projected capital expenditures for 2026 are high, ranging from $175 million to $225 million, which could strain cash flow.
Foreign exchange impact: While foreign exchange is expected to provide a benefit in 2026, it introduces uncertainty and potential volatility in financial results.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Revenue Growth: Total company revenue is expected to grow to a range of $1.233 billion to $1.251 billion, representing 5% to 6.5% constant currency growth and an estimated 100 basis point foreign currency benefit compared to 2025.
Adjusted EBITDA: Expected to improve to a range of $632 million to $641 million, representing 5.5% to 7% constant currency growth and an estimated 100 basis point impact from foreign currency.
Sterigenics Revenue Growth: Expected to deliver mid- to high single-digit constant currency revenue growth year-over-year, with the first quarter anticipated to grow in the mid-single digits range.
Nordion Revenue Growth: Expected to grow constant currency revenue in the low to mid-single digits in 2026, with the first half revenue representing approximately 40% to 45% of full year revenue.
Nelson Labs Revenue Growth: Expected to achieve full year 2026 constant currency revenue growth in the low single digits, with Q1 growth expected to decline low to mid-single digits versus Q1 2025.
Interest Expense: Projected to be between $135 million to $145 million based on the current forward rate curve.
Effective Tax Rate: Expected to range between 27% to 29% applicable to adjusted net income.
Adjusted EPS: Expected to be in the range of $0.93 to $1.01, driven by operational growth and improved interest expense.
Capital Expenditures: Expected to be in the range of $175 million to $225 million in 2026.
Net Leverage Ratio: Continued progress in reducing the net leverage ratio is expected in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the reason behind the 20 basis points of EBITDA margin expansion in the guidance?
A:The expansion is due to normal operating leverage and running the business, with no abnormal factors.
Q:Can you provide more background on the client that chose to outsource sterilization to Sterigenics?
A:The decision was influenced by multiple factors, including new regulations, but the compliance period is still two years away. The customer will start transitioning volume in late 2026, with full transition by 2027-2028.
Q:What are the expectations for Sterigenics in 2026 regarding volume and pricing?
A:Sterigenics is expected to achieve 3-4% price growth, with bioprocessing and MedTech volumes showing continued growth. However, the commercial segment remains challenging.
Q:How will Nelson Labs' margins and revenue progress in 2026?
A:Nelson Labs is expected to maintain low to mid-30% margins, with Q1 being the lightest quarter. Revenue headwinds from expert advisory services will ease after Q1.
Q:Why is Sterigenics expected to have a slower start in Q1 2026?
A:The slower start is due to typical seasonality, shutdowns, and weather impacts. The company is guiding mid-single-digit growth for Q1.
Q:What is the strategy and timeline for the new X-ray facility?
A:The X-ray facility is a strategic investment to offer full-service sterilization. It will open in the second half of 2026, with a ramp period extending into 2027 and 2028.
Q:What drove the 9% year-over-year growth in cross-selling revenue in 2025?
A:The growth was driven by strategic pilots and leveraging the value proposition across Sotera Health's platforms, with several hundred customers contributing to the increase.
Q:What is the company's capital allocation strategy for 2026?
A:The priorities remain funding organic investments, achieving free cash flow targets, and maintaining a balanced approach to CapEx and potential bolt-on acquisitions.
Q:What is the competitive positioning of Sterigenics and Nelson Labs?
A:Sterigenics is well-positioned due to its global platform and full-service offerings. Nelson Labs operates in a fragmented market but excels in service, quality, and customer satisfaction.
Q:What is the status of litigation and its potential impact?
A:There are no significant updates, with no trials scheduled for 2026 except for a public nuisance case in New Mexico in July.
Q:What are the headwinds for Nordion in Q4 2025?
A:The headwinds were due to the timing of Cobalt-60 harvest schedules, which were anticipated and not demand-related.
Q:What is the impact of onshoring trends on the business?
A:The company has not seen significant onshoring investments but is well-positioned to benefit if such trends materialize.
Q:What could drive the company to the higher end of its 2026 guidance range?
A:Higher volumes and favorable mix in Sterigenics and Nelson Labs could push results to the higher end of the range.
Q:What is the outlook for bioprocessing and MedTech volumes?
A:Bioprocessing is expected to grow from a small base, while MedTech volumes are in a strong position and expected to continue growing.
Q:What are the challenges in the commercial segment of Sterigenics?
A:The commercial segment, including food and electronics, has been choppy and is experiencing some shrinkage due to customer redesigns and other factors.
Q:What is the impact of tariffs on Sterigenics' performance?
A:Tariffs have not had a material impact on Sterigenics' performance, with consistent volumes observed.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the second Sterigenics facility, including its modality and location, citing ongoing customer discussions. Additionally, they did not quantify the weather-related headwinds for Sterigenics in Q1 2026 or provide detailed updates on the litigation timeline beyond general comments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisory Services
CEO experience
Capital expenditure
Cobalt harvest
Commission lab
Corporate Secretary
Day Capital
Day progress
Deputy General
EO facility
Expert Advisory
Full Conference
Health Full
Investors section
Nordion currency
Petras
President General
Sterigenics currency
adviser
basis pricing
currency benefit
currency digit
expense depreciation
goal
governance
interest expense
loan debt
mix currency
outlook currency
point currency
pricing volume
rate interest
term loan
track
SHC Transcript
Sotera Health Company (SHC) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reveals solid financial performance with raised EBITDA and EPS guidance, improved interest expenses, and strategic investments like the new X-ray facility. The Q&A indicates confidence in Sterigenics' and Nelson Labs' growth, despite some commercial segment challenges. The market cap suggests moderate sensitivity to positive news, likely resulting in a 2% to 8% stock price increase.
Sotera Health Company (SHC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Sotera Health Company (SHC) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reveals strong financial metrics, including raised revenue and EBITDA growth outlooks, improved net leverage ratio, and increased adjusted EPS guidance. Despite some concerns, such as margin compression and Q4 pullback, the overall sentiment is positive, with consistent performance across key areas and confidence in long-term growth. The market cap suggests moderate volatility, leading to a positive stock price prediction (2%-8%) over the next two weeks.
Sotera Health Company (SHC) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary and Q&A indicate stable financial performance, with positive operating cash flow and improved net leverage ratio. Despite limited guidance for 2026, there is optimism in product development and market strategy, particularly with Sterigenics and Nelson Labs. The company's strong liquidity position and ongoing investments in capacity expansion further support a positive outlook. Given the market cap of approximately $3.37 billion, the stock is likely to experience a moderate positive reaction in the range of 2% to 8% over the next two weeks.
SHC Slides
SHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
